Cognitive Impairment, Vascular Diseases, Alzheimer Disease, Atherosclerosis
Conditions
Keywords
Alzheimer Disease, Cognitive Impairment, 11C-PiB, Atherosclerosis
Brief summary
The investigators will conduct a study of brain positron emission tomography (PET) using 11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City. Participants will be imaged only once with Pittsburgh Compound B (PIB) PET.
Detailed description
This is a single center PET study of 11C-PIB. Eligible participants are current participants in the MESA study in New York City, without contraindications to MRI or PET procedures. Those eligible will have one brain PET scan with 11C-PIB within 12 months of a brain MRI. Vital signs will be checked prior to injection of 11C-PIB, 10 minutes after the injection, and again at the completion of the PET scan. The primary outcome measure for amyloid will be whole brain 11C-PIB SUVR. The relation between exposure groups and amyloid in the brain will be analyzed using linear regression.
Interventions
DRUG11C-PIB
Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
Sponsors
Wake Forest University
National Institute on Aging (NIA)
José A. Luchsinger
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Current participants in MESA study at Columbia University * 60 years or older * Fluent in English and/or Spanish. * Able to participate in all scheduled evaluations and to complete all required tests and procedures.
Exclusion criteria
* Active treatment for cancer * Any serious medical condition which would prevent long-term participation * Pregnancy * Weight \>300 pounds * Participants previously diagnosed or adjudicated to have dementia * Participants unwilling to undergo cognitive testing * Plans to leave the community within five years * Language barrier (speaks other than English, Spanish, Chinese) * Inability to give informed consent or to obtain consent from a Legally Authorized Representative (LAR)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Whole Brain 11C-PIB SUVR | 40 to 90 minutes post injection | Standardized uptake value ratio (SUVR) of 11C-PIB;The extent of Aβ deposition in the brain will be quantified by\[11C\]PiB uptake visualized by PET using standardized uptake volume ratio (SUVR) of 6 primary cortical areas (i.e., anterior cingulate, prefrontal cortex, lateral temporal cortex, posterior parietal cortex, precuneus cortex, and anteroventral striatum) relative to the uptake in the cerebellum |
Countries
United States
Outcome results
None listed